Patient monitoring devices market: size, growth and outlook 2026–2032

Monitors are bought as fleets with central stations and software — standardise across sites. Published estimates normalised to 2025 range from USD 13.5 bn to USD 50.6 bn; the Consulting Wallah central estimate is USD 45.0 bn, growing at about 8% a year to USD 74.7 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by ageing population is the most significant long-term driver (Research and Markets); rising lifestyle diseases: diabetes, cardiovascular, obesity-related (Research and Markets; Polaris); growing adoption of remote patient monitoring and home-care monitoring (Research and Markets).

Context that matters for buyers and suppliers: Global patient monitoring devices market expected to grow from USD 50.553 bn (2025) to USD 74.004 bn (2030) at 7.92% CAGR. Multiparameter patient monitoring market USD 13.54 bn in 2025, to USD 22.19 bn by 2034 (5.6% CAGR); portable devices largest segment. Middle East patient monitoring market USD 1.28 bn (2023), projected USD 2.20 bn by 2030 at 7.8% CAGR. US patient monitoring equipment market >USD 10 bn in 2025; Medtronic largest, Philips second, GE HealthCare third.

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 13.5 bn–USD 50.6 bn; differences are mostly scope.

Included: the product category as named, across hospital, clinic, laboratory and home settings, including the consumables and service contracts that travel with it where sources report them together. Excluded: adjacent categories reported in their own markets. Global figures are quoted as published; regional figures are flagged by scope.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Global patient monitoring devices market expected to grow from USD 50.553 bn (2025) to USD 74.004 bn (2030) at 7.92% CAGR (Research and Markets)
• Multiparameter patient monitoring market USD 13.54 bn in 2025, to USD 22.19 bn by 2034 (5.6% CAGR); portable devices largest segment (Polaris Market Research)
• Middle East patient monitoring market USD 1.28 bn (2023), projected USD 2.20 bn by 2030 at 7.8% CAGR (Next Move Strategy Consulting)
• US patient monitoring equipment market >USD 10 bn in 2025; Medtronic largest, Philips second, GE HealthCare third (iData Research)
• Hospitals accounted for >51.3% and North America >42.7% of patient monitoring revenue in 2020 (Precedence Research via BioSpace)
• Philips leads US multiparameter vital signs and wireless ambulatory telemetry; IntelliVue MX40 is a wearable monitor (iData Research)
• Danaher to acquire Masimo for about USD 9.9 bn (close expected H2 2026) (iData Research)

Where the GCC and India sit

• Middle East patient monitoring market: USD 1.28 bn (2023) — Next Move Strategy Consulting
• Middle East patient monitoring market: USD 2.20 bn (2030) — Next Move Strategy Consulting
• US patient monitoring equipment: over USD 10 bn (2025) — iData Research
• Global patient monitoring devices: USD 50.553 bn (2025) — Research and Markets

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: aI/ML for predictive analytics and automated alerts (Research and Markets; Next MSC); miniaturised wearable monitors and home-based monitoring ecosystems (Research and Markets); value-based care models rewarding measurable outcomes (Research and Markets).

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Hospital leaders: standardise the fleet or the product family across sites, tender on total cost of use with fill-rate and uptime KPIs, and dual-source the top lines — see our five-line scoring.
• Suppliers: GS1 data, in-country stock and service response are the differentiators after price; the Consulting Wallah Network carries GCC and Indian demand in this category.
• Investors: regional manufacturing or service capacity backed by procurement preference.

1. Research and Markets / GlobeNewswire, $74 Bn Patient Monitoring Devices Market Forecasts from 2025 to 2030 — globenewswire.com
2. Polaris Market Research, Multiparameter Patient Monitoring Market Size Worth $22.19 billion by 2034 — polarismarketresearch.com
3. Next Move Strategy Consulting, Middle East Patient Monitoring Market — nextmsc.com
4. iData Research, Top 7 US Patient Monitoring Equipment Companies in 2026 — idataresearch.com
5. BioSpace / Precedence Research, Patient Monitoring Devices Market Size to Rake US$ 83.5 Bn by 2030 — biospace.com
6. Research and Markets (via GlobeNewswire) (2025-12) — USD 50.553 bn (2025) to USD 74.004 bn (2030), CAGR 7.92%; scope: global / patient monitoring devices (hemodynamic, multiparameter, RPM, neuro, respiratory, temperature, cardiac, fetal/neonatal) — source
7. Polaris Market Research (2026) — USD 13.54 bn (2026: USD 14.29 bn) (2025) to USD 22.19 bn (2034), CAGR 5.6% (2026-2034); scope: global / multiparameter patient monitoring sub-segment; portable devices largest 2025; North America largest, Asia Pacific fastest — source
8. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
9. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.